Vertex Pharmaceuticals (VRTX) Work In Process (2011 - 2012)
Vertex Pharmaceuticals (VRTX) posted quarterly Work In Process of $58.5 million for Q3 2012, up 64.45% year-over-year from $35.5 million in Q4 2011, and down 1.3% quarter-over-quarter from $59.2 million in Q2 2012.
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Work In Process (2011 - 2012) Analysis & Trends
Vertex Pharmaceuticals' Work In Process history runs 2 years deep, the most recent figure standing at $58.5 million for Q3 2012.
- In Q3 2012, Work In Process rose 64.45% year-over-year to $58.5 million; the TTM figure through Sep 2012 stood at $58.5 million (up 64.45% YoY), while the FY2011 annual figure was $47.0 million, changed N/A from the prior year.
- Work In Process for Q3 2012 stood at $58.5 million, down from $59.2 million in the prior quarter.
- The five-year high for Work In Process was $74.7 million in Q1 2012, with the low at $10.0 million in Q1 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2012 | 58.45 Mn |
| Jun 30, 2012 | 59.22 Mn |
| Mar 31, 2012 | 74.74 Mn |
| Dec 31, 2011 | 47.01 Mn |
| Sep 30, 2011 | 35.54 Mn |
| Mar 31, 2011 | 10.00 Mn |